In the present study, we analyze safety and effects of allogeneic adipose-derived mesenchymal stem cell transplantation into patients with refractory lupus nephritis, who have acquired resistance to conventional treatment regimens in order to introduce a new approach for treatment of Lupus. This controlled interventional study will be performed on 20 patients with lupus nephritis from whom 10 people will be considered as controls. For interventional group, adipose-derived mesenchymal stem cell will be isolated from adipose tissue of healthy donors between the ages of 18 and 40 years, who had no history of any significant illness and had no physical or mental disability, are selected from members of the patient’s families with HLA matching. The consents are obtained from all patients. Criteria for entrance to the study include decrease in renal function, increase in protein urine (defined as more than 1.0 g of protein excretion in a 24-h urine specimen), Systemic lupus erythematosus disease activity index score of more than 8 (All patients were resistant to at least 3 months of therapy with conventional treatment standard). The exclusion criteria also, involve uncontrolled infection, failure of kidney or other vital organs and so forth. Allogeneic Ad-MSCs are transplanted intravenously at the dose of 2 million cells/kilogram of body weight. All patients are then followed up over the course of 18 months (after a week, one, three, six, twelve and eighteen months) to evaluate renal remission, as well as possible side effects. The patients are evaluated before and after transplantation for clinical changes using the Systemic lupus erythematosus disease activity index and assessment renal function (Glomerular filtration rate, Proteinuria).